Search results for " colore."

showing 10 items of 234 documents

Association of mechanical bowel preparation with oral antibiotics and anastomotic leak following left sided colorectal resection: an international, m…

2018

INTRODUCTION: The optimal bowel preparation strategy to minimise the risk of anastomotic leak is yet to be determined. This study aimed to determine whether oral antibiotics combined with mechanical bowel preparation (MBP+Abx) was associated with a reduced risk of anastomotic leak when compared to mechanical bowel preparation alone (MBP) or no bowel preparation (NBP).METHODS: A pre-planned analysis of the European Society of Coloproctology (ESCP) 2017 Left Sided Colorectal Resection audit was performed. Patients undergoing elective left sided colonic or rectal resection with primary anastomosis between 1 January 2017 and 15 March 2017 by any operative approach were included. The primary out…

Laparoscopic surgeryMaleLeakmedicine.medical_specialtyCathartics/administration & dosagemedicine.drug_classmedicine.medical_treatmentAntibioticsanastomotic leakanastomotic leak; bowel preparation; colonic cancer; Colorectal surgery; laparoscopic surgery; Gastroenterology030230 surgeryAnastomosisPreoperative Care/methodsNO03 medical and health sciences0302 clinical medicineColorectal surgeryAnti-Bacterial Agents/administration & dosagePreoperative CareMedicineHumansrisk factorsProspective StudiesMulti centreProspective cohort studyColectomyAgedta3126Medical Auditbusiness.industryCatharticsdigestive oral and skin physiologyGastroenterologycolonic cancerMiddle Agedlaparoscopic surgeryColorectal surgerydigestive system diseasesSurgeryAnti-Bacterial Agents030220 oncology & carcinogenesisBowel preparationbowel preparationDrug Therapy CombinationFemaleColectomy/adverse effectsbusinessAnastomotic Leak/etiology
researchProduct

The colovescical fistula in diverticular disease: Laparoscopic approach in two different cases

2020

Highlights • The colovescical fistula is one of the complications of diverticular disease. • It can cause typical symptoms like pneumaturia and fecaluria affecting the quality of life and sometimes leading to death, usually secondary to sepsis. • We studied two patients with clinical, radiological and endoscopic diagnosis of colovescical fistula as a consequence of diverticular disease. • We performed a totally laparoscopic treatment with colonic resection and closure of the fistula with intracorporeal sutures. • The presence of a colovescical fistula significantly increases the difficult of the laparoscopic colonic resection.

Laparoscopic surgerymedicine.medical_specialtySurgical skillsmedicine.medical_treatmentFistulaCase ReportLaparoscopic colorectal resection03 medical and health sciences0302 clinical medicineFecaluriaComplicated diverticulitismedicineDysuriaLaparoscopic suturesContraindicationPneumaturiamedicine.diagnostic_testbusiness.industryCystoscopymedicine.diseasedigestive system diseasesSurgery030220 oncology & carcinogenesisDiverticular diseaseLaparoscopy030211 gastroenterology & hepatologySurgerymedicine.symptomColovescical fistulabusinessInternational Journal of Surgery Case Reports
researchProduct

Meta-analysis of mismatch repair polymorphisms within the cogent consortium for colorectal cancer susceptibility

2013

In the last four years, Genome-Wide Association Studies (GWAS) have identified sixteen low-penetrance polymorphisms on fourteen different loci associated with colorectal cancer (CRC). Due to the low risks conferred by known common variants, most of the 35% broad-sense heritability estimated by twin studies remains unexplained. Recently our group performed a case-control study for eight Single Nucleotide Polymorphisms (SNPs) in 4 CRC genes. The present investigation is a followup of that study. We have genotyped six SNPs that showed a positive association and carried out a meta-analysis based on eight additional studies comprising in total more than 8000 cases and 6000 controls. The estimate…

Linkage disequilibriumGenotypeReparació de l'ADNlcsh:MedicineDNA repairGenome-wide association studySingle-nucleotide polymorphismBiologyGenetic polymorphismsDNA Mismatch RepairPolymorphism Single NucleotideDNA Glycosylases03 medical and health sciences0302 clinical medicineMUTYHCàncer colorectalHumansGenetic Predisposition to Diseaselcsh:ScienceGenetic Association Studies030304 developmental biologyGenetic associationGenetics0303 health sciencesMultidisciplinaryGenetic heterogeneityPolimorfisme genèticlcsh:RCase-control studyOdds ratioColorectal cancer3. Good health030220 oncology & carcinogenesisCase-Control Studieslcsh:QColorectal NeoplasmsResearch Article
researchProduct

Hypoxia-inducible factor 1 alpha expression increases during colorectal carcinogenesis and tumor progression

2008

Abstract Background Hypoxia-inducible factor 1 alpha (HIF-1α) is involved in processes promoting carcinogenesis of many tumors. However, its role in the development of colorectal cancer is unknown. To investigate the significance of HIF-1α during colorectal carcinogenesis and progression we examined its expression in precursor lesions constituting the conventional and serrated pathways, as well as in non-metastatic and metastatic adenocarcinomas. Methods Immunohistochemistry and Western blot is used to analyse HIF-1α expression in normal colonic mucosa, hyperplastic polyps (HPP), sessile serrated adenomas (SSA), low-grade (TA-LGD) and high-grade (TA-HGD) traditional adenomas as well as in n…

LipopolysaccharidesCancer ResearchPathologymedicine.medical_specialtyColorectal cancerColonic PolypsMouse model of colorectal and intestinal cancermedicine.disease_causelcsh:RC254-282chemistry.chemical_compoundWestern blotCell Line TumorGeneticsMedicineHumansNeoplasm Metastasismedicine.diagnostic_testbusiness.industrymedicine.diseaseHypoxia-Inducible Factor 1 alpha Subunitlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensImmunohistochemistryVascular endothelial growth factorCell Transformation NeoplasticOncologychemistryHyperplastic PolypTumor progressionDisease ProgressionImmunohistochemistrybusinessCarcinogenesisColorectal NeoplasmsPrecancerous ConditionsResearch ArticleBMC Cancer
researchProduct

Multisciplinary management of patients with liver metastasis from colorectal cancer

2016

Abstract: Colorectal cancer (CRC) is one of the leading causes of cancer-related death. Surgery, radiotherapy and chemotherapy have been till now the main therapeutic strategies for disease control and improvement of the overall survival. Twenty-five per cent (25%) of CRC patients have clinically detectable liver metastases at the initial diagnosis and approximately 50% develop liver metastases during their disease course. Twenty-thirty per cent (20%-30%) are CRC patients with metastases confined to the liver. Some years ago various studies showed a curative potential for liver metastases resection. For this reason some authors proposed the conversion of unresectable liver metastases to res…

Liver metastase0301 basic medicinemedicine.medical_specialtyChemotherapy; Colorectal cancer; Liver metastases; Liver resection; Multidisciplinary team; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Disease Management; Hepatectomy; Humans; Liver Neoplasms; Receptor; Epidermal Growth Factor; GastroenterologyColorectal cancermedicine.medical_treatmentAngiogenesis InhibitorsColorectal NeoplasmReviewChemotherapy; Colorectal cancer; Liver metastases; Liver resection; Multidisciplinary team; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Disease Management; Hepatectomy; Humans; Liver Neoplasms; Receptor Epidermal Growth Factor; GastroenterologyMetastasis03 medical and health sciencesLiver metastases0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCombined Modality TherapyChemotherapyHepatectomyHumansDisease management (health)ChemotherapyAntineoplastic Combined Chemotherapy ProtocolLiver resectionEpidermal Growth Factorbusiness.industryGeneral surgeryHepatobiliary diseaseLiver NeoplasmsGastroenterologyDisease ManagementGeneral MedicineMultidisciplinary teammedicine.diseaseColorectal cancerCombined Modality TherapyRadiation therapyErbB Receptors030104 developmental biologyLiver Neoplasm030220 oncology & carcinogenesisReceptor Epidermal Growth FactorHuman medicineHepatectomybusinessColorectal NeoplasmsAngiogenesis InhibitorHumanReceptor
researchProduct

Estudio de acetilación de proteínas en líneas celulares humanas de cáncer colorectal KRAS mutado y salvaje

2016

El estado mutacional de KRAS es el principal predictor negativo de respuesta a terapias anti-factor de crecimiento epidérmico (EGFR) en pacientes diagnosticados de cáncer colorectal avanzado (CRC). Sin embargo existe datos contradictorios sobre las causas de la respuesta variable a estos fármacos diana de acuerdo con la presencia de mutaciones, de hecho publicaciones recientes han presentado datos no concluyentes sobre los pacientes portadores de mutaciones en el codón 13. En nuestro trabajo, hemos estudiado el impacto de la presencia de mutaciones en KRAS en proteínas intracelulares no histónicas. Para ello hemos utilizado diferentes líneas celulares de cáncer colorectal portadoras de dife…

Líneas celularesCancer ColorectalAcetilación proteícaKRASFármacos anti factor de crecimiento epidérmico
researchProduct

Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.

2016

IF 10.383; International audience; OBJECTIVES: Cancer may be a complication of inflammatory bowel disease (IBD) or its treatment. In elderly onset IBD patients the risk of malignancy is of particular concern. We studied this risk in a population-based cohort of elderly onset IBD patients.METHODS: In a French population-based cohort, we identified 844 patients aged >60 years at IBD diagnosis from 1988 to 2006, including 370 Crohn's disease (CD) and 474 ulcerative colitis (UC). We compared incidence of cancer among IBD patients with that observed in the French Network of population-based Cancer Registries (FRANCIM). Confidence interval (CI) was estimated assuming a Poisson-specific law for ra…

MESH: CarcinomaMaleNonmelanoma Skin-CancerInflammatory bowel disease0302 clinical medicineAdrenal Cortex HormonesAzathioprineMESH: IncidenceAge of OnsetAged 80 and overeducation.field_of_studyMESH: Middle AgedRheumatoid-ArthritisIncidenceGastroenterologyMESH: Follow-Up StudiesMESH: Anti-Inflammatory Agents Non-Steroidal3. Good health030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatology[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Immunosuppressive Agentsmedicine.medical_specialtyMESH: Age of OnsetMESH: Colitis Ulcerativedigestive systemMESH: Adrenal Cortex Hormones03 medical and health sciencesIntestinal NeoplasmsHumansCrohns-DiseaseeducationMESH: Intestinal NeoplasmsMESH: Protective FactorsMESH: AzathioprineAgedRetrospective StudiesMESH: HumansMESH: Crohn DiseaseTumor Necrosis Factor-alphaMESH: Retrospective Studiesmedicine.diseaseMESH: Inflammatory Bowel DiseasesInflammatory Bowel Diseasesdigestive system diseasesLymphoproliferative DisordersMethotrexateMESH: Tumor Necrosis Factor-alphaColitis UlcerativeComplicationMESH: FemaleProspective Observational CohortTime FactorsMESH: RegistriesMESH: Proportional Hazards ModelsMaintenance TherapyMESH: Aged 80 and overMESH: Lymphoproliferative DisordersCrohn DiseaseMESH: Risk FactorsRisk FactorsNeoplasmsMESH: NeoplasmsRegistriesUlcerative-ColitisMesalamineMESH: AgedIncidence (epidemiology)Anti-Inflammatory Agents Non-SteroidalMetaanalysisMiddle AgedhumanitiesMESH: MethotrexateFemaleFranceFrench PopulationColorectal NeoplasmsImmunosuppressive AgentsMESH: Myeloproliferative DisordersPopulationColorectal-CancerIncreased RiskInternal medicinemedicineProportional Hazards ModelsMyeloproliferative DisordersHepatologybusiness.industryMESH: Time FactorsCarcinomaCancerRetrospective cohort study[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: MesalamineProtective FactorsMESH: MaleMESH: FranceAge of onsetbusinessMESH: Colorectal NeoplasmsFollow-Up StudiesThe American journal of gastroenterology
researchProduct

Analysis of RET promoter CpG island methylation using methylation-specific PCR (MSP), pyrosequencing, and methylation-sensitive high-resolution melti…

2016

Background Already since the 1990s, promoter CpG island methylation markers have been considered promising diagnostic, prognostic, and predictive cancer biomarkers. However, so far, only a limited number of DNA methylation markers have been introduced into clinical practice. One reason why the vast majority of methylation markers do not translate into clinical applications is lack of independent validation of methylation markers, often caused by differences in methylation analysis techniques. We recently described RET promoter CpG island methylation as a potential prognostic marker in stage II colorectal cancer (CRC) patients of two independent series. Methods In the current study, we analy…

Male0301 basic medicineMESH: Sequence Analysis DNABisulfite sequencingAnalytic sensitivityMS-HRMMESH : AgedMESH : Promoter Regions GeneticPolymerase Chain Reaction[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineMESH: DNA MethylationMESH : FemaleMESH : Proto-Oncogene Proteins c-retPromoter Regions GeneticMESH: CpG IslandsMESH : Polymerase Chain ReactionGenetics (clinical)MESH: AgedDNA methylationMESH : PrognosisMethylationMESH : CpG IslandsPrognosispyrosequencing030220 oncology & carcinogenesisMESH: Survival AnalysisDNA methylationFemaleMESH : Colorectal NeoplasmsMESH : Sensitivity and SpecificityColorectal NeoplasmsMESH : Male[SDV.CAN]Life Sciences [q-bio]/CancerBiologySensitivity and SpecificityMESH: Proto-Oncogene Proteins c-retHigh Resolution MeltMESH: Prognosis03 medical and health sciencesMESH: Promoter Regions GeneticGeneticsHumansMolecular BiologyAgedMESH: HumansResearchMSPProto-Oncogene Proteins c-retMESH : HumansMESH: Polymerase Chain ReactionSequence Analysis DNASurvival AnalysisMolecular biologyMESH: Sensitivity and SpecificityMESH: Male030104 developmental biologyPyrosequencingIllumina Methylation AssayCpG IslandsCancer biomarkersClinical sensitivityPrimer (molecular biology)MESH : Survival AnalysisRETMESH: FemaleMESH : DNA MethylationMESH: Colorectal NeoplasmsDevelopmental BiologyMESH : Sequence Analysis DNA
researchProduct

Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic …

2016

[Purpose] TAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Efficacy and safety of TAS-102 in patients with metastatic colorectal cancer (mCRC) refractory or intolerant to standard therapies were evaluated in the phase 3 RECOURSE trial. Results of RECOURSE demonstrated significant improvement in overall survival (OS) and progression-free survival (PFS) with TAS-102 versus placebo [hazard ratio (HR) = 0.68 and 0.48 for OS and PFS, respectively; both P < 0.001]. The current analysis evaluates efficacy and safety of TAS-102 in the RECOURSE Spanish subgroup.

Male0301 basic medicineOncologyCancer ResearchPyrrolidinesColorectal cancerTrifluridineHelsinki declarationlaw.inventionTrifluridinechemistry.chemical_compound0302 clinical medicineRandomized controlled triallawMedicineAged 80 and overMetastatic colorectal cancerPalliative CareHazard ratioGeneral MedicineMiddle AgedPrognosisTAS-102Survival RateDrug CombinationsOncology030220 oncology & carcinogenesisDrug Therapy CombinationFemaleColorectal NeoplasmsFluoropyrimidineResearch Articlemedicine.drugAdultmedicine.medical_specialtyanimal structuresSubgroup analysisPlaceboAntiviral Agents03 medical and health sciencesDouble-Blind MethodInternal medicineHumansTipiracil hydrochlorideUracilAgedNeoplasm StagingTipiracilbusiness.industrymedicine.diseaseSurgery030104 developmental biologychemistrySpainbusinessThymineFollow-Up StudiesClinical and Translational Oncology
researchProduct

Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic th…

2017

// Gemma Bruera 1, 2 , Antonio Russo 3 , Antonio Galvano 3 , Sergio Rizzo 3 and Enrico Ricevuto 1, 2 1 Oncology Territorial Care, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L’Aquila, L’Aquila, Italy 2 Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy 3 Medical Oncology, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy Correspondence to: Antonio Russo, email: antonio.russo@usa.net Keywords: elderly, intensive treatment, metastatic colorectal cancer, triplet chemotherapy plus bevacizumab, unfit Received: June 07, 2016     Accepted: November 24, 2016     Published:…

Male0301 basic medicineUnfitmedicine.medical_specialtyBevacizumabColorectal cancerDecision MakingAngiogenesis InhibitorsNeutropeniamedicine.disease_cause03 medical and health sciences0302 clinical medicineElderlyInternal medicinemedicineMucositisHumansNeoplasm MetastasisAgedRetrospective StudiesTriplet chemotherapy plus bevacizumabbusiness.industryMetastatic colorectal cancerelderly; intensive treatment; metastatic colorectal cancer; triplet chemotherapy plus bevacizumab; unfitRetrospective cohort studymedicine.diseaseComorbiditySurgeryRegimenTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisFemaleIntensive treatmentKRASClinical Research PaperColorectal NeoplasmsbusinessElderly; Intensive treatment; Metastatic colorectal cancer; Triplet chemotherapy plus bevacizumab; Unfit; Oncologymedicine.drug
researchProduct